Quick Answer
Cocrystal Pharma, Inc. reported Stockholders Equity of $6.33 million for the year ending 2025.
- Cocrystal Pharma, Inc. showed a decrease of -33.5% in Stockholders Equity from 2024 to 2025.
- This data is from Cocrystal Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2012: -$3.58 million | Q1 2013: -$5.06 million | Q2 2013: -$5.29 million | Q3 2013: -$10.45 million | Q1 2014: -$2.07 million | Q2 2014: $6.06 million | Q3 2014: $3.98 million | Q1 2015: $188.70 million | Q2 2015: $196.52 million | Q3 2015: $196.75 million | Q1 2016: $169.34 million | Q2 2016: $166.83 million | Q3 2016: $167.82 million | Q1 2017: $99.98 million | Q2 2017: $102.04 million | Q3 2017: $100.00 million | Q1 2018: $104.14 million | Q2 2018: $112.65 million | Q3 2018: $110.90 million | Q1 2019: $73.82 million | Q2 2019: $72.42 million | Q3 2019: $70.75 million | Q1 2020: $40.43 million | Q2 2020: $37.06 million | Q3 2020: $50.18 million | Q1 2021: $52.06 million | Q2 2021: $84.75 million | Q3 2021: $81.01 million | Q1 2022: $73.58 million | Q2 2022: $49.39 million | Q3 2022: $49.91 million | Q1 2023: $34.67 million | Q2 2023: $34.68 million | Q3 2023: $30.69 million | Q1 2024: $22.59 million | Q2 2024: $17.39 million | Q3 2024: $12.70 million | Q1 2025: $7.30 million | Q2 2025: $5.33 million | Q3 2025: $7.67 million.
- Over the full 17 years of available data (2009 to 2025), Cocrystal Pharma, Inc.'s Stockholders Equity has grown by 2,896.9%.
- Historical annual values: Fiscal year 2025: $6.33 million | Fiscal year 2024: $9.52 million | Fiscal year 2023: $26.38 million | Fiscal year 2022: $39.60 million | Fiscal year 2021: $77.55 million | Fiscal year 2020: $52.51 million | Fiscal year 2019: $25.71 million | Fiscal year 2018: $66.89 million | Fiscal year 2017: $105.40 million | Fiscal year 2016: $102.32 million | Fiscal year 2015: $167.59 million | Fiscal year 2014: $6.65 million | Fiscal year 2013: -$8.83 million | Fiscal year 2012: -$5.01 million | Fiscal year 2011: -$2.77 million | Fiscal year 2010: -$589.2 thousand | Fiscal year 2009: -$226.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: